Croda International Plc, a company that uses smart science to create high-performance ingredients and solutions, has recently announced a new acquisition. The nearly 100 year old company has announced the acquisition of Solus Biotech, a world leader in the manufacture of premium, biotechnology-derived active ingredients for beauty care and pharmaceutical products.
Solus Biotech specialises in the manufacture of high purity, naturally derived ceramides and phospholipids obtained through yeast fermentation. Their biomimetic structure, similar to the lipid components of human skin, offers excellent skin barrier enhancement, hydration and multiple exceptional benefits.
Croda confirms that this is a significant development for Croda, and is aligned with its strategic priorities, as Solus consolidates its position as a world leader in sustainable assets, builds its biotech knowledge base, expands a manufacturing and innovation facility in North Asia and brings a wealth of intellectual property and knowledge.
The immediate priorities are to establish Croda's core values, particularly safety, and to integrate Solus' natural ingredients into the global sales network. It will also support the Solus team with technical and R&D expertise, particularly in key areas such as formulation development.